4-Methylmorpholine → 2-[N-[4-(1-tert-Butoxycarbonylpiperidin-4-yloxy)phenyl]-N-(4-methoxycarbonyl-benzoyl)aminomethyl]-5-cyano-1-(4-benzyloxyphenylcarbamoylmethyl)-benzimidazole

HRID 412546ノート

反応式

HRID 412546 の反応式
[C:1]([O:5][C:6]([N:8]1[CH2:13][CH2:12][CH:11]([O:14][C:15]2[CH:20]=[CH:19][C:18]([N:21]([CH2:34][C:35]3[N:39]([CH2:40][C:41](O)=[O:42])[C:38]4[CH:44]=[CH:45][C:46]([C:48]#[N:49])=[CH:47][C:37]=4[N:36]=3)[C:22](=[O:33])[C:23]3[CH:28]=[CH:27][C:26]([C:29]([O:31][CH3:32])=[O:30])=[CH:25][CH:24]=3)=[CH:17][CH:16]=2)[CH2:10][CH2:9]1)=[O:7])([CH3:4])([CH3:3])[CH3:2].O.ON1C2C=CC=CC=2N=N1.Cl.[CH2:62]([O:69][C:70]1[CH:76]=[CH:75][C:73]([NH2:74])=[CH:72][CH:71]=1)[C:63]1[CH:68]=[CH:67][CH:66]=[CH:65][CH:64]=1.Cl.CN(C)CCCN=C=NCC.CN1CCOCC1>>[C:1]([O:5][C:6]([N:8]1[CH2:13][CH2:12][CH:11]([O:14][C:15]2[CH:16]=[CH:17][C:18]([N:21]([CH2:34][C:35]3[N:39]([CH2:40][C:41](=[O:42])[NH:74][C:73]4[CH:72]=[CH:71][C:70]([O:69][CH2:62][C:63]5[CH:64]=[CH:65][CH:66]=[CH:67][CH:68]=5)=[CH:76][CH:75]=4)[C:38]4[CH:44]=[CH:45][C:46]([C:48]#[N:49])=[CH:47][C:37]=4[N:36]=3)[C:22](=[O:33])[C:23]3[CH:24]=[CH:25][C:26]([C:29]([O:31][CH3:32])=[O:30])=[CH:27][CH:28]=3)=[CH:19][CH:20]=2)[CH2:10][CH2:9]1)=[O:7])([CH3:4])([CH3:3])[CH3:2]

参加物

6

反応物 5

HCID 79724-MethylmorpholineHCID 27238314-Benzyloxyaniline hydrochlorideHCID 27239391,3-Propanediamine, N'-(ethylcarbonimidoyl)-N,N-dimethyl-, monohydrochlorideHCID 27960291-Hydroxybenzotriazole hydrateHCID 185364772-[N-[4-(1-tert-Butoxycarbonylpiperidin-4-yloxy)phenyl]-N-(4-methoxycarbonylbenzoyl)aminomethyl]-5-cyanobenzimidazole-1-acetic acid

生成物 1

HCID 185365182-[N-[4-(1-tert-Butoxycarbonylpiperidin-4-yloxy)phenyl]-N-(4-methoxycarbonyl-benzoyl)aminomethyl]-5-cyano-1-(4-benzyloxyphenylcarbamoylmethyl)-benzimidazole収率 75.3%

実験手順

2-[N-[4-(1-tert-Butoxycarbonylpiperidin-4-yloxy)phenyl]-N-(4-methoxycarbonylbenzoyl)aminomethyl]-5-cyanobenzimidazole-1-acetic acid (632 mg), 1-hydroxybenzotriazole hydrate (128 mg), 4-benzyloxyaniline hydrochloride (223 mg), 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (182 mg) and N-methylmorpholine (0.104 ml) were treated in the same manner as in Example 17, Step 10. The solvent was evaporated and the obtained residue was purified by silica gel column chromatography (hexane:ethyl acetate=3:7-2:8) to give the title compound (605 mg).

後処理

  1. customThe solvent was evaporated
  2. customthe obtained residue was purified by silica gel column chromatography (hexane:ethyl acetate=3:7-2:8)

出典と根拠

ORDレコード
ord-15560a0139cd4e73b31dafef9908e927
出典データセット
uspto-grants-2003_05
特許番号
US06562828B1

反応ノート

読み込み中…